Optimizing Induction Therapy for Newly Diagnosed Multiple Myeloma: Navigating the Treatment Options
Ajay K. Nooka, MD, MPH, FACP
Accredited Activity
Targeting B-cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma: New Findings in Clinical Context
Robert Z. Orlowski, MD, PhD; Nikhil C. Munshi, MD; Nina Shah, MD
Accredited Activity
Sequencing Treatment in Relapsed/Refractory Multiple Myeloma: The Right Treatment at the Right Time for the Right Patient
Paul G. Richardson, MD
Accredited Activity
Recent Activities by Topic
- VIDEO: Practice Essential - Novel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma - Shaji K. Kumar, MD
- VIDEO: FAQ - Four-drug combination regimen now approved in multiple myeloma - Shaji K. Kumar, MD
- VIDEO: FAQ - What are emerging perspectives and strategies in the early intervention of smoldering myeloma? - Noopur Raje, MD
- VIDEO: FAQ - What factors do you consider when choosing treatment in newly diagnosed multiple myeloma? - Shaji K. Kumar, MD
- ASH MHM: "SYMPOSIUM REPLAY" - The Art and Science of RRMM: A Practical Guide to Complex Therapeutic Choices - Parameswaran Hari, MD and Saad Z. Usmani, MD, FACP
- VIDEO: Practice Essential - Incorporating MRD Testing into Standard Practice: Are We There Yet? - Faith Davies
- eNewsletter - Treatment Options in Relapsed/Refractory Multiple Myeloma: Caring for the Patient During the First Relapse and Beyond
- Sagar Lonial, MD, FACP
- VIDEO: Clinical Expert Commentaries - Key Presentations in Multiple Myeloma from ASH 2018 - Sagar Lonial, MD
- VIDEO: Clinical Expert Commentaries - Read More
Phase 3 Randomized Study of D-Rd Versus Rd in Patients with NDMM Ineligible for Transplant - Saad Z. Usmani, MD, FACP
- VIDEO: FAQ - New option in the prevention of bone complications in patients with multiple myeloma - Noopur Raje, MD
- VIDEO: FAQ - Updates on the bb2121 clinical trial: What is the future of CAR-T cell therapy in multiple myeloma? - Noopur Raje, MD